Endocrine Abstracts

Background: The Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide has shown improvements in glycaemia and other metabolic parameters for patients with type 2 diabetes (T2D) in clinical trials. Published real-world data are sparse and there are none from the Middle East where semaglutide became available in 2020.Method and Results: We retrospectively gathered data for 289 patients (median age 50 years (IQR 42-57), 36% female, 87% Emirati and 8...

We report the case of a 28-year-old Emirati lady with type 1 diabetes (weight 51 kg, BMI 20.82 kg/m2) diagnosed at 3 years of age who presented to our centre with problems at her insulin injection sites. She had poor glycaemic control and her diabetes was complicated by retinopathy; other past medical history included vitamin D deficiency. All her seven siblings had diabetes and were on insulin; both parents had type 2 diabetes.In 2017, she wa...

IntroductionMelanocortin-4-receptor (MC4R) deficiency is the commonest of the rare monogenic forms of obesity. Bariatric surgery (BS) is the most efficacious treatment modality in the more ’common’ polygenic obesity. Effect of surgical and drug treatment in obesity due to MC4R deficiency is not well-established.AimWe aimed to explore the effects of BS and drug treatment among the confirmed cases of ...